Table 6.

IL5RA expression levels and clinical parameters in pretreatment and after 3 months of benralizumab treatment.

	Eosinophils/μl	IL5RA, relative expression	FEV1, ml	FeNO, ppb	ACT
Patient 1
Pretreatment	630	1.8	1,897	43	13
3 months	10	0.6	2,462	68	22
Patient 2
Pretreatment	820	29.2	1,960	-	8
3 months	10	1.2	2,520	-	24
Patient 3a
Pretreatment	437	10.9	2,310	154	12
3 months	0	1.0	3,100	113	22
Patient 4
Pretreatment	1,290	62.5	1,890	66	19
3 months	0	4.7	2,840	198	25
Patient 5a
Pretreatment	630	12.6	2,060	65	12
3 months	10	0.8	2,630	64	21

^aPatients previously treated with other biological drugs, but no improvement was observed.